The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer